Sign in with Google. Opens in new tab
ENTITY

Bluebird Bio (BLUE US)

11
Analysis
Health CareUnited States
Bluebird Bio, Inc. provides biotechnological products and services. The Company offers gene therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders, and beta-thalassemia. Bluebird Bio conducts its business in the United States.
more
24 May 2023 10:33

CRISPR Therapeutics AG (CRSP US): First Genome Editing Based Drug Candidate Seeking FDA Approval

CRISPR completed regulatory submissions for exa-cel (world’s first CRISPR gene editing drug) in US and awaits FDA action date. Exa-cel has the...

Logo
579 Views
Share
bullishCSL Ltd
04 Apr 2023 12:06

CSL Ltd (CSL AU): Looking into New Engines for Sustainable and Profitable Growth

New management, upcoming product launch in US, diversification into kidney disease, plasma collection recovery, and rich pipeline indicate an...

Logo
444 Views
Share
bullishHelixmith
25 Aug 2022 10:24

Helixmith (084990 KS): Overhang on Phase 3 Clinical Trial Uncertainty Got Removed

Helixmith has received much awaited IDMC recommendations for phase 3 clinical trial for its lead candidate Engensis in diabetic neuropathy in US,...

Logo
505 Views
Share
07 Jun 2021 06:29

CARsgen Therapeutics IPO: Valuation Insights

Due to the full IPO price range, lack of blue-chip cornerstone support and the current weak market sentiment on IPOs, we are inclined to wait on...

Logo
509 Views
Share
26 May 2021 17:08

CARsgen Therapeutics IPO Initiation: Choosing Therapies À La CAR-T

CARsgen is pre-marketing an HKEx IPO to raise proceeds of $400-500m. The promising prospects for the lead product, credible management and a good...

Logo
398 Views
Share
x